AN3 Ca
Marca : CLS Cell Lines Service
AN3 Ca Cells
General information
Description | The An3 Ca cell line is derived from a human endometrial adenocarcinoma, a type of cancer originating from the lining of the uterus. This cell line is estrogen receptor negative (ER-) and exhibits aggressive tumorigenic potential when assessed in vivo. An3 Ca cells are used extensively in research focused on understanding the molecular and cellular mechanisms underlying endometrial cancer progression, including studies on cancer cell proliferation, metastasis, and response to therapeutic agents. Characteristically, An3 Ca cells display an epithelial morphology and have been utilized to study the impact of various genetic and environmental factors on cancer cell behavior. Research using this cell line has contributed to identifying potential therapeutic targets and understanding the resistance mechanisms against conventional treatments. They serve as a valuable model for evaluating new drugs or treatment strategies that could be effective against aggressive forms of endometrial cancer. Overall, the An3 Ca cell line is instrumental in advancing the scientific knowledge of endometrial adenocarcinoma, offering insights that might lead to more effective interventions for this challenging and often lethal disease. |
---|---|
Organism | Human |
Tissue | Uterus, Endometrium |
Disease | Adenocarcinoma |
Synonyms | AN3_CA, AN3-CA, AN3 Ca, AN3CA, AN-3, AN3, Acanthosis Nigricans 3rd attempt-CArcinoma |
Characteristics
Age | 55 years |
---|---|
Gender | Female |
Ethnicity | Caucasian |
Morphology | Epithelial-like |
Cell type | Epithelial |
Growth properties | Adherent |
Identifiers / Biosafety / Citation
Citation | AN3 Ca (Cytion catalog number 300119) |
---|---|
Biosafety level | 1 |
Expression / Mutation
Isoenzymes | PGM3, 1-2, PGM1, 1, ES-D, 1, AK-1, 1-2, GLO-1, 2, G6PD, B, |
---|---|
Tumorigenic | Yes, in nude mice. Produces undifferentiated malignant tumor, also at low frequency (22%) in the cheek pouch of cortisone treated hamsters |
Ploidy status | Aneuploid, Phenotype Frequency Product: 0.0054 |
Handling
Culture Medium | EMEM, w: 2 mM L-Glutamine, w: 1.5 g/L NaHCO3, w: EBSS, w: 1 mM Sodium pyruvate, w: NEAA (Cytion article number 820100c) |
---|---|
Medium supplements | Supplement the medium with 10% FBS |
Passaging solution | Accutase |
Doubling time | 45 to 50 hours |
Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
Split ratio | A ratio of 1:3 to 1:6 is recommended |
Seeding density | An initial seeding density of 3 to 4 x 10^4 cells/cm^2 is recommended. Later on, 2 x 10^4 cells/ cm^2 will yield a confluent layer in 4 to 5 days. |
Fluid renewal | 2 to 3 times per week |
Freezing recovery | Within 24 to 48 hours |
Freeze medium | CM-1 (Cytion catalog number 800100) or CM-ACF (Cytion catalog number 806100) |
Handling of cryopreserved cultures |
|
Quality control / Genetic profile / HLA
Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
---|---|
STR profile | Amelogenin: x,x CSF1PO: 12,14,15 D13S317: 12,14 D16S539: 10,14,15 D5S818: 11,14 D7S820: 7.1,10 TH01: 9.3,10 TPOX: 8,10 vWA: 14,19,20,21 D3S1358: 17 D21S11: 29,30 D18S51: 15,17,18 Penta E: 9,16 Penta D: 9,16 D8S1179: 12,14 FGA: 23 D1S1656: 13,18.3 D6S1043: 12,13,14,15,18 D2S1338: 20,23 D12S391: 20,21,23,24,25 D19S433: 14 |
HLA alleles | A*: 03:01:01 B*: 44:02:01, 57:01:01 C*: 05:01:01, 06:02:01 DRB1*: 04:01:01G, 16:01:01 DQA1*: 01:02:02, 03:01:01 DQB1*: 03:02:01, 05:02:01 DPB1*: 05:01:01G, 13:01:01G E: 01:03:02 |